Sk Pharmteco

SK pharmteco has been serving as a Global CDMO since January 2019, specializing in the commercial and clinical production of both small and large molecules. SK pharmteco offers a comprehensive range of services that includes process R&D, analytical method development, stability studies, scale-up and optimization, and the validation and commercial production of APIs, Advanced Intermediates, Registered Starting Materials, and Key Building Blocks. Additionally, SK pharmteco provides development, analytical services, and CGMP production for Cell Therapy, Viral Vectors, and Plasmids. Concurrently, SK biotek and SK biotek Ireland Limited have also engaged in contract development and manufacturing since November 2017, showcasing a strong commitment to the CDMO sector in the biopharmaceutical industry.